| Overview |
| bs-0591R-A350 |
| DR4 Polyclonal Antibody, ALEXA FLUOR® 350 Conjugated |
| WB |
| Human |
| Specifications |
| ALEXA FLUOR® 350 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human DR4 |
| 401-468/468 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 8797 |
| O00220 |
| Cell membrane |
| DR4; APO2; CD261; TRAILR1; TRAILR-1; Tumor necrosis factor receptor superfamily member 10A; Death receptor 4; TNF-related apoptosis-inducing ligand receptor 1; TRAIL receptor 1; TRAIL-R1; TNFRSF10A |
| Receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF-kappa-B. |
| Application Dilution |
| WB |
1:300-5000 |
Powered by Bioz